Competitive Intelligence
Week ending August 9, 2026
1. Competitive landscape snapshot (this week)
AI answers about Cosentyx most often named Taltz (17 mentions), followed by Humira (16) and Stelara (16), then Enbrel (15). Lower-volume names were Remicade (6), Skyrizi (3), Tremfya (1), and Bimzelx (1).
At least 28 mentions among the top four came from explicit head-to-head questions: seven responses each to the Cosentyx comparisons with Taltz, Humira, Stelara, and Enbrel. Taltz also appeared in switching and broader biologic questions, making its total the highest. The remaining mentions were largely contextual or incidental—for example, competitors listed as examples of other biologic classes or dosing schedules.
2. How the comparison is currently framed
The dominant framing is neutral, balanced, and hedged, rather than clearly favoring Cosentyx or a competitor.
- Taltz: All seven direct comparison answers recommend shared decision-making and describe both products as legitimate options. The recurring framing is “both are reasonable options,” with differences discussed through dosing, access, tolerability, comorbidities, and patient preference.
- Humira: Answers consistently say both products can be highly effective, while distinguishing IL-17A versus TNF-α mechanisms, response speed, and side-effect patterns. One excerpt references “higher skin clearance rates,” which could make Cosentyx sound stronger, but the surrounding answers emphasize individual response and avoid a universal winner.
- Stelara: The comparison is practical and mechanism-based. AI often portrays Stelara as more widely spaced in maintenance dosing, while Cosentyx is described as having a more frequent loading phase followed by monthly dosing. This creates a modest convenience advantage for Stelara, but not an overall competitive preference.
- Enbrel: The answers explicitly reject “stronger versus weaker” framing and focus on different mechanisms and condition-specific outcomes.
overclaim_language co-occurred heavily with competitor comparisons—particularly all seven Taltz responses and all seven Enbrel responses—but the language was usually presented as wording to avoid (“best,” “superior,” or “stronger”), not as an AI-endorsed claim favoring either product.
3. Movers — who’s gaining or losing ground
Versus August 2, every tracked competitor increased in raw mentions except Bimzelx, which declined from 2 to 1:
- Humira: +9 to 16
- Stelara: +9 to 16
- Taltz: +8 to 17
- Enbrel: +8 to 15
- Remicade: +4 to 6
- Skyrizi: +2 to 3
- Bimzelx: −1 to 1
- Tremfya: unchanged at 1
The increase coincides with responses returning from 60 to 140, so it is primarily a volume rebound rather than proof of share gain. Across the three-week history, Taltz remains the most consistently mentioned competitor; Humira and Stelara have also risen from 7 to 16 this week. No competitor newly entered the conversation this week. Skyrizi was the most recent entrant, appearing last week and increasing again this week.
4. Questions worth watching
- Cosentyx versus Taltz: the highest-volume direct comparison and the clearest recurring IL-17 competitive frame.
- Cosentyx versus Humira in plaque psoriasis: repeated discussion of effectiveness, onset, and side-effect trade-offs.
- Cosentyx versus Stelara: a potentially meaningful convenience comparison centered on dosing frequency.
- Switching from another IL-17 biologic to Cosentyx: Taltz appears in three responses, with insurance/prior authorization described as the biggest practical issue.
5. Recommended actions
- Monitor Taltz next week: it leads at 17 mentions and remains the most persistent competitor across all three weeks.
- Track Humira and Stelara separately: both reached 16 mentions, but their framing differs—clinical outcome comparison for Humira versus dosing convenience for Stelara.
- Flag the Stelara dosing narrative for competitive awareness: AI is repeatedly associating Stelara with more widely spaced maintenance dosing.
- Continue routine monitoring of Enbrel: high mention volume, but current answers remain explicitly noncommittal rather than favoring Enbrel.
- Avoid interpreting this week’s raw increases as a market shift until normalized over another week: total response volume more than doubled, while inconsistency flags rose only from 26 to 27.